Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Jun;112(2):649-53.
doi: 10.1111/j.1476-5381.1994.tb13124.x.

Effects of glibenclamide on systemic and splanchnic haemodynamics in conscious rats

Affiliations

Effects of glibenclamide on systemic and splanchnic haemodynamics in conscious rats

R Moreau et al. Br J Pharmacol. 1994 Jun.

Abstract

1. The effects of the sulphonylurea, glibenclamide (20 mg kg-1, i.v.), at a dose that blocks vascular potassium channels, on systemic and splanchnic haemodynamics (radioactive microspheres) were studied in conscious rats. 2. Glibenclamide significantly decreased cardiac index and hepatic artery blood flow while it significantly increased vascular resistance in systemic, portal and hepatic arterial territories. 3. In rats with suppressed cardiovascular reflexes, glibenclamide induced vasoconstriction in systemic, portal and hepatic arterial territories. 4. Intracerebroventricular administration of glibenclamide did not alter systemic or regional vascular tone. 5. Glibenclamide blunted the vasodilator effect of the potassium channel opener, diazoxide but not that of the L-type calcium channel blocker, nicardipine. 6. Another sulphonylurea, glipizide (20 mg kg-1, i.v.), induced significant systemic and splanchnic vasoconstriction. 7. Thus, the glibenclamide-induced blockade of vascular potassium channels caused a vasoconstriction in the systemic and splanchnic vascular beds. In these territories, therefore, the opening of glibenclamide-sensitive potassium channels might be responsible for a basal vasodilator tone.

PubMed Disclaimer

References

    1. Am J Physiol. 1985 Oct;249(4 Pt 1):G528-32 - PubMed
    1. J Clin Endocrinol Metab. 1993 Jan;76(1):38-43 - PubMed
    1. Annu Rev Neurosci. 1988;11:97-118 - PubMed
    1. J Pharmacol Exp Ther. 1989 Jan;248(1):149-56 - PubMed
    1. Eur J Pharmacol. 1988 Aug 2;152(3):331-9 - PubMed

LinkOut - more resources